---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000059"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:36:28.270957+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA

## Summary
- Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).
- Smallpox MCM revenue down 40% to $64.2M; Anthrax MCM down 55% to $21.6M.
- Adjusted EBITDA $35.6M (23% margin) vs $79.1M (36% margin) in Q1 2025.
- FY 2026 adjusted net income guidance raised to $45-65M (from $25-45M); FY 2026 adjusted EBITDA guidance raised to $155-175M (from $135-155M).
- Completed debt refinancing with $150M term loan; secured over $200M in new U.S./Canada government contracts.

## SEC filing metadata
- accession: 0001367644-26-000059
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000059
- JSON: https://secwatch.observer/filing/0001367644-26-000059.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000059.txt

## Key facts
- Earnings Releases
  Emergent BioSolutions Inc. reported first quarter ended March 31, 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.
  - Period: first quarter ended March 31, 2026
  - Revenue: $156.1 million
  - Net income: $6.8 million
  - EPS: $0.07
  - Result: reported results
  source text: and is incorporated herein by reference. --- EX-99.1 (EX-99.1) --- EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS • First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm
- Earnings Releases
  Emergent BioSolutions Inc. reported Q1 2026 results: revenue $156.1, net income $6.8, EPS 0.07.
  - Period: Q1 2026
  - Revenue: $156.1
  - Net income: $6.8
  - EPS: 0.07
  - Result: reported results
  source text: ($ in millions, except per share amounts) Q1 2026 Q1 2025 % Change Total Revenues $ 156.1 $ 222.2 (30) % Net Income $ 6.8 $ 68.0 (90) % Net Income per Diluted Share $ 0.07 $ 1.19 (94) %
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm
- Earnings Releases
  Emergent BioSolutions Inc. reported First Quarter 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.
  - Period: First Quarter 2026
  - Revenue: $156.1 million
  - Net income: $6.8 million
  - EPS: $0.07
  - Result: reported results
  source text: First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.